---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-083543"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:38:53.940815+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CVRx Q2 2024 revenue up 24% to $11.8M; net loss widens to $14.0M; updates FY guidance

## Summary
- Q2 2024 revenue $11.8M (+24% YoY); U.S. HF revenue $10.5M (+27% YoY); net loss $14.0M ($0.65/share) vs $11.6M ($0.56) in Q2 2023.
- Active implanting centers in U.S. reach 189, up 35% YoY; sales territories expanded to 42 from 39 in Q1.
- Cash and equivalents $70.4M; net cash used in operating/investing $10.2M in Q2, down from $11.8M in Q1.
- Hired Robert John as CRO, Dr. Philip Adamson as CMO, and other execs to strengthen commercial efforts.
- FY 2024 guidance: revenue $50-53M; gross margin 83-85%; operating expenses $95-98M (narrowed from $92-98M); Q3 revenue $12.7-13.7M.

## SEC filing metadata
- accession: 0001104659-24-083543
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465924083543/0001104659-24-083543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465924083543/tm2420331d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-083543
- JSON: https://secwatch.observer/filing/0001104659-24-083543.json
- Plain text: https://secwatch.observer/filing/0001104659-24-083543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.